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Immune checkpoint inhibitors have revolutionized cancer therapy, but not all cancers respond to the currently
available drugs, and even within cancers considered responsive to such modality, response rates range between
15 and 40%, depending on the cancer type, the line of treatment, and yet unknown clinical/molecular factors.
Coordinated expression of checkpoint proteins was shown to occur on T cells, probably allowing fine-tuning of
the signal transmitted to the cell.
We performed a bioinformatic analysis of the expression of putative checkpoint mRNAs at the cancer side of the
immunological synapse from the bladder cancer tumorgenome atlas (TCGA) database. Fifteen mRNAs,
corresponding to both coinhibitory and costimulatory checkpoints, were shown to be expressed above a
designated threshold. Of these, seven mRNAs were found to be coexpressed: CD277, PD-1L, CD48, CD86,
galectin-9, TNFRSF14 (HVEM), and CD40. The expression of 2 of these mRNAsdBTN3A1 (CD277) and TNFRSF14
(HVEM)dwas positively correlated with overall survival in the TCGA database. All these seven mRNA share
putative binding sites of a few transcription factors (TFs). Of these, the expression of the TF BACH-2 was
positively correlated with the expression of checkpoint mRNAs from the network. This suggests a joint
transcriptional regulation on the expression of checkpoint mRNAs at the bladder tumor side of the immunological
synapse.
Translational Oncology (2020) 13, 193–200© 2019 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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There is an ongoing revolution in clinical oncology in the last decade
following the realization that cancer develops an entire range of
mechanisms to evade the host's immune response [1]. Extensive
research is aimed at studying the cellular interface between cancer or
antigen presenting cells (APCs) and lymphocytes, designated “the
immunological synapse.” Immune checkpoint proteinsdnamely,
transmembrane proteins coexpressed at both the cancer/APC and the
lymphocyte side of immunological synapsedserve to modulate the
signal transmitted from the cancer to the T cell, leading to either
proliferation and activation (a costimulatory effect) or anergy and
exhaustion (a coinhibitory effect) [2].
Three families of monoclonal antibodies targeting checkpoint
inhibitors are already approved and being used to treat cancerd
anti-CTLA4 (targeting the coinhibitory protein CTLA4 on T cells),
anti-PD1 (targeting the coinhibitory protein PD-1 on T cells), and
antiePD-1L (targeting the coinhibitory protein PD-1L on cancer
cells). Notwithstanding these major advancements, not all cancers
respond to the currently available immune checkpoint inhibitors, and
even within cancers considered responsive to such modality, response
rates range between 15 and 40%, depending on the cancer type, the
line of treatment, and yet unknown clinical/molecular factors.
Urothelial carcinoma of the bladder has long been perceived to be
an immunogenic malignancy, and indeed intrabladder immune
modulation with Bacillus CalmetteeGuerin has been the mainstay of
treatment for high-risk nonmuscle invasive bladder cancer (BLCA)
for decades. Recently, both anti-PD1 and antiePD-1L antibodies
were shown to have activity in metastatic urothelial carcinoma of the
bladder, with response rates ranging between 16 and 25%, depending
on the trial and the agent [3e5]. There are now many ongoing
clinical trials with combinations of immune checkpoint modulators
in BLCA. Clearly, a better understanding of the immunological
synapse in BLCA is warranted to advance immunotherapeutic
treatment in this disease.
Previously, the expression of costimulatory and coinhibitory
checkpoint proteins on the surface of T cells was shown to be
coordinated and concerted (reviewed in Ref. [6]), symbolically
metaphorized to resemble a tide wave of checkpoint protein activation
[7]. Our hypothesis was that a similar coordinated expression of
checkpoint proteins may occur on the cancer side of the
immunological synapse, potentially allowing fine-tuning of the signal
transmitted to the T cells. Here, we provide a bioinformatic analysis
of coexpression networks of checkpoint mRNAs, based on the cancer
genome atlas (TCGA) database,1 providing insights on potential new
checkpoint genes that mandate further experimental research in this
disease. We also point to a few transcription factors (TFs) that may be
involved in the regulation of expression of these checkpoint genes,
thus suggesting new potential targets for anticancer therapies.
Materials and Methods
Data Acquisition and Preprocessing
mRNA expression and metadata of the cases were acquired from
The Cancer Genome Atlas (TCGA) [1] database using the1TCGA has been recently moved to the NIH-owned platform, known today as
Genomic Data Commons Data Portal, and remains under the US government law
protection. Nevertheless, most of data remained publicly available for research
purposes.“TCGAbiolinks” package in R [8]. We obtained the BLCA dataset
(TCGA-BLCA), which consists of 412 tumor samples. For
correlation aliases, we used the results of “HTSeq-FPKM” workflows
for mRNA. We discarded duplicates of the same patient and selected
only for experiments where matching sample was profiled for gene
expression and miRNA expression. This resulted in a cohort of 405
tumor samples, which was later used for all correlation analyses. We
also analyzed 21 samples of normal bladder urothelium (“controls”).
Of note, healthy tissue samples marked as “controls” were derived
from the same patients from which the tumor samples were derived.
Based on the literature, 22 genes potentially expressed at the
cancer/APC side of the immunological synapse were selected for this
analyses: PD-L1, PD-L2, CD40, CD48, CD70, CD80, CD86,
CD112, CD137L, CD200, CD276, CD266, Gal-9, OX40L,
HVEM, PVR, ICOSL, VTCN1, GITRL, VISTA, HHLA2, and
IDO1. A comprehensive list of these checkpoints, their versatile
names, and their suggested functions at the synapse is given in
Table 1.Correlation Analyses
We selected mRNAs of interest and created an n x m numeric
matrix expression measures of reads per million per kilobase of
transcript for RNA-seq or normalized qPCR values for PCR-based
assays, where n is number of experiments (405 in case of BLCA
cohort) and m is number of preselected mRNAs. We then generated a
nonparametric correlation matrix using Spearman's rank-order
correlation coefficient implemented in R. The statistical significance
of each correlation is determined using a correlation testda t-test is
applied to the individual correlations using the following formula:
t ¼ r* sqrt(n-2)/sqrt(1-r^ 2). This method is implemented in “psych”
package. The p values are then corrected to q-values using the false
detection rate (FDR) method [9]. The resulting correlations and
associated q-values are visualized for further inspection using
“corrplot” package in Rdour variation of the plot shows correlation
values in lower triangle and q values in circles in the upper triangle of
the heatmap-like plot [10].Graphical Model Estimation
Correlation graphs represent the correlation matrix with nodes that
indicate genes of interest and edges that represent correlation values.
Green edges indicate positive correlations and red edges negative
ones. The width of the edges and their color saturation corresponds to
the absolute value of correlations and scale relative to the strongest
weight in the graph. The graphs are organized as “spring” layout,
which uses the FruchtermaneReingold algorithm [11] to obtain a
force-directed layout. In this solution, each node (connected and
unconnected) repulse each other, and connected nodes also attract
each other. After a number of iterations (500), a final logout is
reacheddthe distance between the nodes corresponds well to
correlation between the nodesdcorrelated nodes are close to each
other, while anticorrelated (negative correlation) nodes are moved to
distant parts of the graph.Boxplots of Expression Values
Boxplots shows the FPKM values from primary solid tumor (PT)
and normal tissue (NT). The p-values estimating statistical
significance of difference between PT and NT are calculated using
ManneWhitneyeWilcoxon U-test.
Table 1. A List of All Potential Checkpoints on the Cancer/APC Side if the Immunological Synapse.
On a Tumor Additional Names On an Immune System Cell (T Cells Mostly) Coinhibitory () or Costimulatory
(þ) or Unknown (?)
MHC I/II TCR Signal 1
MHC I/II KIR 
MHC I/II LAG3 (CD223) 
CD80 B7-1, B7-H1, CD28LG, CD28LG1, LAB7, BB1 Binds to CD28 (þ) or CTLA-4 ()
CD86 B7-2, B7-H2, FUN-1, BU-63, B70, LAB72, CD28LG2, Binds to CD28 (þ) or CTLA-4 ()
CD276 B7-H3, B7-3 Binds to CD28 (þ) or CTLA-4 ()
VTCN1 B7-H4, B7-4 Binds to CD28 (þ) or CTLA-4 ()
VISTA B7-H5, B7-5, PD-1H, Gi24, VSIR ?
HHLA2 B7-H7 TMIGD2 (IGPR-1) 
PD-L1 CD274, PDCD1LG1, B7-H1 Binds to PD-1 
PD-L2 CD273, PDCD1LG2, B7-DC Binds to PD-1 
CD277 BTN3A, BT3.1, BTF5 ?
CD134L TNFSF4, OX40L Binds to OX40 (TNFRSF4) þ
CD137L TNFSF9, 4-1BBL Binds to 4-1BB receptor (TNFRSF9) þ
CD70 TNFSF7, CD27L TNFRSF7, CD27 þ
B7RP1 ICOSL ICOS þ
CD112 NECTIN2, HVEB, PVRL2 TIGIT 
CD226, DNAM-1 þ
CD112R 
CD200 MOX1, MOX2, MRC, OX2 CD200R 
CD48 BCM-1, BLAST-1 CD244, 2B4 þ
Gal-9 LGALS9, galectin-9, LGALS9A, HUAT, Tumor Antigen HOM-HD-21 Binds to galactosides, HAVCR2, TIM3 
GITRL TNFSF18, TL6, HGITRL, AITRL, TNLG2A TNFRSF18, GITR, AITR, CD357 þ
CD40 TNFRSF5, P50 TNFSF5 (CD40LG, CD154, IGM, IMD3, HIGM1, T-BAM, GP39) þ
HVEM TNFRSF14, HVEA, TR2, LIGHTR, ATAR, CD270 BTLA, HVEML, LIGHT, CD270L, TNFSF14 
PVR PVC, CD155, NECL5, TAGE4, HVED VTN (vitronectin)
CD96 
CD226, DNAM-1 þ
TIGIT 
IDO IDO1, TDO Y tryptophan 
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Gene promoter sequences were obtained from Homo sapiens
reference genome (hg38) using the Biostrings package in R. We
defined promoters as regions 2000 bp upstream to 200 bp
downstream annotated transcription start site (TSS) as customary
(https://www.cell.com/molecular-cell/fulltext/S1097-2765(15)
00262-2). Gene coordinates were obtained directly from TCGA
annotations used in the RNA-seq pipeline. To find and analyze
motifs, we used tools from MEME suit12: MEMEdfor de novo
motif discovery [12], CentriMo [13]dto assess the central motif
enrichment at promoter regions and TomTomdto find similar
motifs in known motif databases. We ran two types of analysesdlong
motif search, where we de novo searched the whole 2.2 kb sequence at
once, and short motif search, where we splatted the promoter
sequence into 33 tiles of 100 bp that overlap by 25 bp. For each
MEME output, we calculated central enrichment and annotated the
motif using the search against known motif databases.Figure 1. Expression of checkpoint mRNAs in bladder cancer
and normal samples in the TCGA database.Results
The expression of 22 checkpoint mRNA suggested to be on the
cancer/APC side of the immunological synapse is seen in Figure 1. Of
these, 21 are transmembrane checkpoints (excluding IDO1 that
codes for an intracellular protein). Fifteen had a median expression
level of above 1 transcript per million, chosen here as the expression
cutoff (Table 2). These include the coinhibitory molecules: PD-L1,
CD276, galectin-9, CD200, and TNFRSF14 (HVEM); the
costimulatory molecules: CD40, CD48, ICOSLG and CD137L;
the molecules VTCN1, CD112, CD86, and PVR, probably
implicated in both types of interactions (depending on their T-cell
counterpart); and VISTA and CD277, the effect of which is currentlyuncertain. Of these, the median expression of CD276, PVR, and
CD112 is significantly higher in tumor than in NT, and the median
expression of VISTA, CD48, and CD200 is significantly lower in
tumor than in NT (Figure 2).
We then checked for correlations in the expression of these 15
mRNAs, calculating the Spearman rho correlation coefficient of each
possible pair. Using a rho correlation coefficient cutoff of 0.5 to be
statistically significant (corresponding to an adjusted q value of 0.1 or
less following FDR correction for multiple comparisons), 7 mRNAs
were found to be coexpressed: CD277, PD-1L, CD48, CD86,
galectin-9, TNFRSF14 (HVEM), and CD40 (Figure 3). The
Table 2. Median Expression of 15 Checkpoint mRNAs in
Bladder Tumor Samples in the TCGA Database.
mRNA Name Median TPM
PVRL2 95.0
CD276 71.0
LGALS9 67.2
HVEM 49.5
CD40 20.4
VISTA 16.9
PVR 13.5
BTN3A1/CD277 12.9
CD48 6.3
ICOSLG 5.0
CD200 3.8
VTCN1 3.5
CD86 3.4
CD274/PD-1L 1.1
TNFSF9/CD137L 1.1
Figure 3. Correlation matrix with Spearman rho values (bottom
triangle) and q-values (upper triangle, in circles) of 7 checkpoint
mRNAs, based on TCGA data. Tonation and size of the values
are associated with the strength of correlation.
196 Immunological Synapse in Bladder Cancer Dobosz et al. Translational Oncology Vol. 13, No. 2, 2020coexpression network is depicted in Figure 4. To verify that these
seven genes are indeed significantly coexpressed, we checked all 6435
combinations of 7 genes out of 15. The connectivity of each of these
6435 potential networks was scored using 3 methodsdcalculating
the mean correlation of the network; using the network coefficients
described by Onnela and colleagues; and using the network
coefficients of Zhang and Horvath (the last two described in
Ref. [14]) According to all 3 methods, the abovementioned seven
genes were significantly more connected that any other combination,
with mean p values of 0.00062, 0.0047, and 0.018 for the 3 methods,
respectively.
Of these 7 checkpoint mRNAs, the expression of 2 of these
mRNAsdBTN3A1 (CD277) and TNFRSF14 (HVEM)dwas
correlated with overall survival in the TCGA database (Figure 5).
Last, we searched the putative promoter sites for potential TF
binding motifs common to all of the seven coexpressed genes. Because
in most cases the promoter is not known, the standard promoter
length used for analyses was 2000 base pairs (bp) upstream and 200
bp downstream of the TSS. The following TFs were found to have
putative motifs in the promotors of all seven coexpressed mRNAs:
MAFK, BACH-1, BACH2, NFE2L2, TFAP2A, TFAP2B, TFAP2C,
MEIS2, MEIS3, PKNOX1, PKNOX2, TGIF1, and TGIF2
(Figure 6). To assess whether these 13 motifs are indeed significantly
overrepresented in these 7 promotors, we performed a hypergeo-
metric test for the overrepresentation of these motifs against a set of
1000 randomly selected promoter sets of 7 genes. We found that all
13 motifs were significantly overrepresented, with p-values rangingFigure 2. Differential analysis of 15 selected genes. Expression
synapse in bladder cancer tumor tissue and in normal bladder tisfrom 3.51*105 for MEIS1 to 0.026 for TFAP2B. This indicates that
the occurrence of these common motifs in the 7 putative promotors
cannot be explained by mere change and suggests that indeed the TFs
take part in regulating the coexpression of these 7 checkpoint genes.
Of these 13 TFs, only the expression of BACH-2 was positively
correlated with the expression of 2 checkpoint mRNAs with the
networkdnamely CD86 and CD48dusing the same rho cutoff of
0.5. The expression of BACH2 was also correlated with the
expression of the CD200, which was in itself borderline correlated
with the expression of CD48. There was a nonsignificant trend of
positive correlation between the expression of BACH-2 and PD-L1
(CD274; rho ¼ 0.4, q ¼ 0.2). Figure 7 depicts a comprehensive
network of all checkpoint mRNAs and BACH-2 mRNA.
Discussion and Conclusions
Using bioinformatic tools and analyses, we show here that of 21
transmembrane checkpoint genes potentially expressed on the cancer
side of the synapse, the mRNA of 15 is expressed above a designatedlevel of genes involved in the formation of the immunological
sue in the TCGA database.
Figure 4. Expression correlation network of selected 7
checkpoint mRNAs with the rho values  0.5, based on
Spearman rho coefficients. Green line indicates positive
correlations, and line thickness reflects the strength of the
correlation.
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with potentially costimulatory and coinhibitory functions. Of these,
the expression of 7 is highly correlated to one another, and a high
expression of 2 of thesedHVEM and CD277dis associated with
better prognosis in the TCGA database. All the putative promotor
sites of these 7 mRNAs contain potential binding motifs for several
TFs. Of these TFs, the expression of BACH-2 has a positive
correlation with the expression of several components of the
checkpoint mRNA network.
Our analysis reveals that the mRNAs CD276, galectin-9, HVEM,
PVRL2, and PVR, all suggested to have coinhibitory or mixed
functions, are expressed at significantly higher levels than PD-1L
mRNA. There have been dozens of clinical trials with agents targeting
the PD1/PD-1L axis in recent years, and several of these monoclonal
agents have been approved for treatment of BLCA in the last year or
two. Still, most patients do not respond to single agent anti-PD1/
PD-1L inhibition in BLCA, mandating a deeper understanding of the
intricate immunological synapse in this disease.Figure 5. KaplaneMeier survival curves of bladder cancer patients
(right panel) above (red) or below (green) the median.A recent review summarized the expanding repertoire of potential
targets for immune modulation in the bladder and pointed out
CD276, HHLA2, and VTCN1 as such [15]. Our results
corroborate this review as well as previous research showing the
CD276 mRNA and protein are expressed in BLCA [16] and
contribute to the accumulating evidence of its role in BLCA. CD276
expression promotes invasion and metastasis of urothelial cancer cells
in vitro [17], and clinical trials with the anti-CD276 antibody
MGA271 [18] are under way (www.clinicaltrials.gov). HHLA2
mRNA was not expressed in the TCGA database of BLCA, and
VTCN1 was only expressed at low levels. Galectin-9 protein
expression was also shown to be associated with prognosis in BLCA
[19]. HVEM, PVRL2, and PVR have not been implicated in BLCA
so far to our knowledge, but recently encouraging clinical activity of a
monoclonal antibody against nectin-4 (PVRL4) conjugated to a
microtubule-disrupting agent was presented [20]. Our results further
strengthen the notion that PD-1L is not necessarily the most
important or potent coinhibitory checkpoint in BLCA.
The expression of seven of these mRNAsdCD277, CD48,
CD86, PD-1L, galectin-9, HVEM, and CD40dwas found to be
significantly correlated to one another. This coexpression resembles
the coexpression of checkpoint mRNAs at the T-cell interface of the
synapse [6,21]. If these results are corroborated at the protein level,
then their implication is that coinhibition occurs concurrently by
several checkpoints. In such circumstances, targeting a single
checkpoint coinhibitor, or even two, may not suffice, as is indeed
seen in most patients.
Three TFs have putative binding sites in the promotors of the
coexpressed checkpoint genes: MAFK, BACH2, and NFE2L2.
BACH2 TF has recently been reported as crucial in several pathways
related to the immune system functioning [22,23]. It is also involved
in NF-kB signaling pathway that is in itself cardinal in BLCA
pathogenesis [23]. Aberrant function of BACH2 has been already
implicated in several cancer types, such as lymphomas [24]. MAFK is
a powerful transcription regulator, in a form of leucine zipper,
cooperating with NFE2 TFs family, hence acting as a transcription
silencer or enhancer, depending on the protein interactions [24,25].from the TCGA with mRNA expression of HVEM (left) or CD277
Figure 6. Common TF-binding motifs in the putative promoters of the 7 coexpressed checkpoint mRNA with their orientation and
calculated p value.
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NFE2 TFs, blocking their binding sites [25e27].
The correlation between BACH-2 expression and the checkpoint
mRNA network, taken with its putative ability to regulate the
expression of these mRNAs, warrants further experimental research. If
indeed checkpoint mRNAs, and consequently proteins, are coregu-
lated, then this may open novel avenues for modulating the
expression of checkpoints at the immunological synapse.The expression of two mRNAsdHVEM (TNFRSF14) and
CD277 (BTN3A1)dwas positively associated with survival of
BLCA patients. CD277 is a member of the butyrophilin subfamily
3 that shares significant sequence similarities and predicted common
structural features with other members of the B7 superfamily. It was
shown to be expressed in the microenvironment of ovarian cancer
[28] and pancreatic adenocarcinoma [29]. Butyrophilin 3 A isoforms
are critical activating molecules of Vg9Vd2 T cells [29], and their
Figure 7. Expression correlation network of all checkpoint
mRNAs (red nodes) and the BACH-2 transcription factor (blue
node), based on Spearman rho coefficients. Green lines
represent positive correlations, and red lines represent negative
ones. Line thickness represents the strength of the correlation.
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indirectly hint to the importance of Vg9Vd2 T cells in eliciting an
antineoplastic response in this tumor type.
HVEM (TNFRSF14) interacts with multiple ligands expressed in
the immune system including the TNF superfamily cytokines, and its
interactions with its ligands can be altered in pathologic settings,
resulting in dysregulated immune response. It has mainly been
implicated in several types of lymphoma and also in nonhematolo-
gical cancers such as melanoma. Its function as a coinhibitor or
costimulator of T cells seems to be context-dependent (reviewed in
Ref. [30]), and a specific role for it in BLCA has not yet been
described.
There are several important limitations to our work. First, our
results are based on retrospective analysis of a single, albeit large and
well-curated, database. Our proposed networks should therefore be
verified by others as well. Second, our analysis is based on the
expression of mRNAs and not proteins. A comprehensive analysis of
protein expression and proteineprotein interactions at the cancer cell
membrane is mandatory. Second, the mRNA expression measured in
the TCGA samples does not necessarily stem from expression on the
cancer cells but is rather a composite measurement of expression on
all cell types within the microenvironment; having said that, we claim
that it still represents a summation of tumor checkpoint mRNA
expression as a whole. Last, we used here arbitrary, if customary,
cutoffs for both expression and coexpression. Using different cutoffs
would have slightly altered the components of the suggested
networks, but not the essence of our findings.
With the advancement of the field of cancer immunotherapy, the
main target of treatment has shifted from cancer cells themselves to
entire cancer microenvironments, including immune cells and
stromal components. Addressing the particular tumor characteristics,
changing cancer immune set points and modulating the delicate
interactions between tumor cells and immune cells are currently all
major strategies aimed at enhancing the patient's ability to combat the
disease (reviewed, for example, in Ref. [31]). Our work contributes to
the body of accumulating evidence as to the nature of
tumoreimmuneecell interactions at the immunological
synapse and opens up novel avenues for further experimental and
translational research.Funding
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